title: [Evaluation of the antiviral therapy for chronic hepatitis C in patients unresponsive to previous treatment with regard to the interleukin-28B genotypes].
abstract: The identification of the single nucleotide polymorphisms (SNP) at rs8099917 and rs12979860 loci of IL-28B gene is presently necessary for patients with the genotype HCV-1 to predict sustained viral response (SVR) in case of combined antiviral therapy with interferon and ribavirin. In addition to the implementation of the antiviral activity of IFN-α, interleukin-1β (IL-1β) and interferon-gamma (IFN-γ) are involved. The goal of this work was to evaluate the efficacy of the HCV therapy with cytokines in patients unresponsive to previous therapy with unfavorable genotypes of IL-28B gene. SVR was achieved in 44.4% of patients with an unfavorable IL-28B genetic background with biochemical response without serious adverse effects or unexpected adverse effects, thereby corroborating the inclusion of proven safety Betaleukin® and Ingaron in the schemes of the antiviral therapy in combination with standard interferon-α and ribavirin in patients with recurrent HCV-infection.
authors.forename: V Ch
authors.initials: VCh
authors.lastname: Fazylov
authors.forename: S V
authors.initials: SV
authors.lastname: Tkacheva
authors.forename: E R
authors.initials: ER
authors.lastname: Manapova
authors.forename: F M
authors.initials: FM
authors.lastname: Jakupova
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000008:administration & dosage*; D005260:Female; D016174:Hepacivirus; D019698:Hepatitis C, Chronic / Q000188:drug therapy / Q000235:genetics; D006801:Humans; D007372:Interferons; D007378:Interleukins / Q000235:genetics*; D008297:Male; D020641:Polymorphism, Single Nucleotide; D000095022:Interferon Lambda
chemical_list: D000998:Antiviral Agents; D007372:Interferons; D007378:Interleukins; C000624353:interferon-lambda, human; D000095022:Interferon Lambda